-
Gluetacs Therapeutics Files IND for Molecular Glue Degrading Agent in China
•
Gluetacs Therapeutics has reported filing an Investigational New Drug (IND) application for its first molecular glue degrading agent with the Center for Drug Evaluation in China. The company, which specializes in the development of small molecule drugs via protein degradation technology, has also secured an undisclosed amount of investment from…
-
Global Cord Blood Corporation Appoints Liquidators Amid Shareholder Dispute
•
Global Cord Blood Corporation (OTCMKTS: CORBF) has announced that the Grand Court of the Cayman Islands has appointed provisional liquidators and suspended the powers of the company’s directors. This follows a compulsory winding-up petition filed by GCBC’s majority shareholder, Blue Ocean Structure Investment Co., Ltd. As a result of the…
-
Hansoh Pharmaceutical Licenses KiOmedine One for Osteoarthritis Treatment
•
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced a licensing agreement with Belgium’s KiOmed Pharma SA, securing exclusive development and commercialization rights to KiOmedine One for the treatment of osteoarthritis in mainland China, Macau, and Taiwan. Under the agreement, Hansoh will be responsible for the development, regulatory filing,…
-
Ubrigene Raises Hundreds of Millions in Series C Financing Round
•
Yiming (Beijing) Cell Biotechnology Co., Ltd, also known as Ubrigene, a gene and cell therapy contract development and manufacturing organization (CDMO) founded in Beijing in 2015, has reportedly raised “hundreds of millions” of renminbi in a Series C financing round. The round was led by Goldstone Investment and CLSA Capital,…
-
China’s First Proton Therapy System Approved by NMPA
•
The National Medical Products Administration (NMPA) has approved the proton therapy system developed by Shanghai APACTRON Particle Equipment Co., Ltd for marketing as an innovative product. This marks a significant milestone as it is the first proton therapy system developed in China, supported by the Ministry of Science and Technology…
-
Brii Biosciences Publishes Positive Phase I Results for PPD Therapy BRII-296
•
China-based Brii Biosciences Limited (HKG: 2137) has published the top-line results from a Phase I study for its long-acting, single-injection therapy for postpartum depression (PPD), BRII-296. The open-label, single ascending dose Phase I study assessed the safety, tolerability, and pharmacokinetics (PK) of BRII-296 as a single-injection treatment option for PPD…
-
Sino Biopharmaceutical’s TDI01 Receives Clinical Trial Approval for COVID-19
•
China’s Sino Biopharmaceutical Ltd (HKG: 1177) has announced that its subsidiary, Beijing Tide Pharmaceutical Co. Ltd, has received clinical trial approval from the National Medical Products Administration (NMPA) for its in-house developed Category 1 drug TDI01. The targeted indication for the drug is COVID-19. TDI01: Unique Mechanism and DevelopmentTDI01 stands…
-
China Resources Pharma Reports Strong Interim Results Amid COVID-19
•
China Resources Pharmaceutical Group Co., Ltd (HKG: 3320) has published its 2022 interim financial report, revealing a strong performance despite disruptions caused by COVID-19. During the period, the company generated revenues of HKD 12.57 billion ($1.6 billion), up 9.8% year-on-year (YOY), and net profits of HKD 6.168 billion ($785.7 million),…
-
Sciwind Biosciences Partners with SynerK for siRNA Therapeutics Development
•
Hangzhou Sciwind Biosciences Co., Ltd has announced a research partnership with SynerK Inc. The collaboration aims to jointly discover and develop new therapeutics based on small interfering RNA (siRNA) technology to address unmet medical needs in the treatment of liver and metabolic diseases. Financial details of the partnership were not…
-
Arctic Vision Administers First Injection of ARVN001 for Uveitis Macular Edema
•
China-based ophthalmic therapies developer Arctic Vision has announced the first injection of triamcinolone acetonide suprachoroidal injection suspension (ARVN001) in a patient with uveitis macular edema (UME) at the Boao Super Hospital in Hainan’s medical pilot zone. This marks the first application of suprachoroidal injection therapy in Lecheng, facilitated by the…
-
Synthgene Partners with Micor&Nano for Comprehensive Solutions in Nucleic Acid Drugs
•
China-based Jiangsu Synthgene Biotechnology Co., Ltd has entered into a partnership with compatriot firm Micor&Nano (Shanghai) Technology Co., Ltd. The collaboration, focused on nucleic acid drugs, aims to provide comprehensive solutions ranging from raw materials to equipment and processes. Partnership Focus and ObjectivesSynthgene, a leading upstream raw material supplier for…
-
ThunderBio Secures Funding from Guangzhou LBP for PCR Innovation
•
ThunderBio Innovation Limited, a specialist in droplet microfluidics and molecular diagnostics based in Zhejiang, has raised an undisclosed amount of funding from Guangzhou LBP Medicine Science & Technology Co., Ltd. The collaboration will focus on advancing digital polymerase chain reaction (PCR) technology, including product research and development (R&D), manufacturing, and…
-
Fujian Cosunter Receives NMPA Approval for COVID-19 Drug Candidate GST-HG171
•
China-based Fujian Cosunter Pharmaceutical Co., Ltd (SHE: 300436) has announced that it has received approval from the National Medical Products Administration (NMPA) to conduct a clinical study for its Category 1 drug candidate, GST-HG171, in adult patients with mild/common COVID-19. This marks a significant step forward in the development of…
-
Everest Medicines Gains CDE Approval for EVER001 Phase Ib Study
•
China-based biotech Everest Medicines (HKG: 1952) has announced that it has received approval from the Center for Drug Evaluation (CDE) in China to conduct a Phase Ib clinical study assessing the safety, efficacy, pharmacokinetics, and pharmacodynamics of its EVER001. The drug candidate, a next-generation covalent reversible Bruton’s tyrosine kinase (BTK)…
-
Boston Scientific Completes First Surgery with RotaPro in China
•
US-based Boston Scientific Corporation (NYSE: BSX) has announced the completion of the first surgery using its RotaPro rotational atherectomy system at Ruijin Hospital’s Hainan Hospital (Boao research-oriented hospital) branch. This procedure marks the first clinical application of the product in China, facilitated by the “first pilot, first trial” scheme, which…
-
Sihuan Pharmaceutical Reports Decline in Revenues Amid COVID-19 Lockdowns
•
China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has released its 2022 interim report for the first six months of the year. The firm reported RMB 1.464 billion ($204.3 million) in revenues, down 23.2% year-on-year (YOY). The decline was attributed to COVID-19 related lockdowns in the domestic market. Business Segment…
-
Shuangcheng Pharma Licenses US Rights for Paclitaxel Injection to Meitheal
•
China’s Hainan Shuangcheng Pharmaceutical Co., Ltd (SHA: 002693) has announced a licensing and supply agreement with US-based Meitheal Pharmaceuticals, Inc., and compatriot firm Hong Kong King-Friend Industrial Co., Ltd. The agreement grants the two companies exclusive rights to Shuangcheng’s paclitaxel for injection (albumin-bound, 100mg/vial) in the US market. Meitheal will…
-
HEC Pharma Overturns Patent Decision Against Novartis’ Gilenya
•
China-based generics firm HEC Pharma has managed to overturn a previous final decision in a patent dispute with Swiss pharmaceutical giant Novartis AG (NYSE: NVS) over the multiple sclerosis blockbuster drug Gilenya (fingolimod). In January 2022, the US Court of Appeals for the Federal Circuit (CAFC) had dismissed an appeal…
-
Nerviano Medical Sciences Collaborates with Merck on PARP1 Inhibitor NMS-293
•
Italy-based Nerviano Medical Sciences S.r.l. (NMS), which is 90% owned by Chinese investment fund SARI under a deal that closed in 2018, has unveiled a collaboration and licensing deal with Germany-based Merck Healthcare KGaA. The agreement grants Merck global rights to develop and commercialize the poly (ADP-ribose) polymerase 1 (PARP1)…
-
Moderna’s CMO Expresses Eagerness to Bring mRNA Vaccines to China
•
The Chief Medical Officer (CMO) of US-based Moderna Inc. (NASDAQ: MRNA), Paul Burton, has been reported as saying that the company is “eager” to bring its mRNA-based COVID-19 vaccines to China. According to sources, Moderna’s chief executive Stephane Bancel disclosed last week that the company has engaged in talks with…
